

Microscopic Colitis

Background

1. Definition
 - Chronic inflammatory bowel dz encompassing both lymphocytic colitis and collagenous colitis
2. General info
 - Collagenous colitis:
 - Thickening of subepithelial basement membrane of colonic mucosa w/ a band of collagen
 - Lymphocytic colitis:
 - Intraepithelial lymphocytosis w/o collagen thickening

Pathophysiology

1. Pathology of dz
 - Not completely known
 - Normal radiologic and colonoscopic appearance of colon
 - Abnormal histologic appearance of colon
 - Leads to chronic watery diarrhea w/o bleeding
2. Incidence and prevalence
 - Incidence of 10 per 100,000 person-years
 - Lymphocytic: 5.4 per 100,000
 - Collagenous: 4.6 per 100,000 ²
 - Prevalence of 103 per 100,000 person-years
 - Lymphocytic: 63.7 per 100,000
 - Collagenous: 39.3 per 100,000
3. Risk factors
 - Pt characteristics ²
 - Older age
 - Female
 - Assoc autoimmune dz ⁴
 - Hypothyroidism
 - Celiac dz
 - Diabetes mellitus
 - Rheumatoid arthritis
 - Asthma
 - Allergies
4. Morbidity/mortality
 - Not assoc w/ incr mortality or severe deterioration
 - No incr risk of neoplasia

Diagnostics

1. History
 - Intermittent, chronic, non-bloody, watery diarrhea
 - Diarrhea up to 2 L or 4-9 episodes/d
 - Vague abdominal pain
 - Fecal urgency
 - Weight loss
 - Fatigue
 - Nausea
2. Physical exam
 - Unremarkable
 - Vague abdominal tenderness
 - Weight loss
3. Diagnostic testing
 - Laboratory evaluation
 - ESR may show slight elevation
 - Autoantibodies found in half of patients
 - RF, ANA, antimitochondrial antibodies, and anti-neutrophil cytoplasmic antibodies
 - Tissue transglutaminase antibody or antiendomysium antibody to rule out celiac dz
 - Stool culture to rule out infectious cause
 - Incr levels of stool inflammatory markers
 - Eosinophil protein X, myeloperoxidase, and tryptase
 - Diagnostic imaging
 - Normal radiologic appearance of colon
 - Other studies
 - Normal colonoscopic appearance of colon
 - Colon biopsy for Dx
 - Number and location of biopsies not established
 - Proximal biopsies improve sensitivity

Differential Dx

1. Key DDx
 - Irritable bowel syndrome
 - Ulcerative colitis
 - Crohn's dz
 - Diverticulitis
 - Ischemic colitis
 - Drug-induced colitis
 - Infectious colitis
 - Lactose intolerance
 - Celiac dz
2. Extensive DDx
 - Hyperthyroidism
 - Carcinoid syndrome

- VIPoma
- Colon cancer
- Other causes of abdominal pain and chronic diarrhea

Therapeutics

1. Reassure pt:
 - Dz has not been assoc w/ colonic neoplasia, incr mortality, or severe deterioration
2. Discontinue any offending drugs
3. Budesonide
 - Start at 9 mg/d for 4 wk
 - Treat over a 6-8 wk period
 - If in remission
 - Taper to 6 mg for 2 wk
 - Then 3 mg for 2 wk
 - Then discontinue
 - May continue dose of 9 mg/d for 12 wks before tapering if Sx are not controlled or if Sx recur on tapering 7,8
4. Bismuth subsalicylate
 - Nine 262 mg tablets daily in 3 divided doses for 8 wk trial is reasonable in pt w/collagenous colitis 7
5. Mesalamine
 - 800 mg TID with or w/o cholestyramine
 - 4 g daily may be effective for pts w/active collagenous or lymphocytic colitis 7,8
6. Loperamide
 - May be used for symptomatic Tx of diarrhea
7. Boswellia serrata extract, prednisolone and probiotics
 - No evidence on effectiveness
8. Surgery
 - Rarely recommended or reported
 - Ileostomy may be procedure of choice in older pts w/severe, resistant dz

Follow-Up

1. Return to office
 - As needed if not responding to Tx
2. Refer to specialist
 - Not indicated unless refractory to Tx
3. Admit to hospital
 - Only if unable to manage as outpatient (rare)

Prognosis

1. Dz course variable w/alternating remissions and relapses
 - Good long-term prognosis
2. Not assoc with incr mortality or severe deterioration

3. 80% resolve spontaneously in less than 3 yrs ⁵
4. Recurrence is common despite Tx ⁹
5. No incr risk of neoplasia

Prevention

1. Limit drugs assoc w/dz
2. Limit dietary factors that may exacerbate condition
 - Caffeine, alcohol, dairy products

Patient Education

1. <http://digestive.niddk.nih.gov/ddiseases/pubs/collagenouscolitis/>

References

1. Sveinsson OA, Orvar KB, Birgisson S, Jonasson JG. Microscopic colitis – review. *Laeknabladid*. 2008 May;94(5):363-70.
2. Williams JJ, Kaplan GG, Makhija S, Urbanski SJ, Dupre M, Panaccione R, Beck PL. Microscopic colitis-defining incidence rates and risk factors: a population-based study. *Clin Gastroenterol Hepatol*. 2008 Jan;6(1):35-40.
3. Pardi DS, Loftus EV, Smyrk TC, Kammer PP, Tremaine WJ, Schleck CD, Harmsen WS, Zinsmeister AR, Melton LJ, Sandborn WJ. The epidemiology of microscopic colitis: a population based study in Olmsted County, Minnesota. *Gut*. 2007 Apr;56:504 - 508.
4. Nyhlin N, Bohr J, Eriksson S, Tysk C. Systematic review: microscopic colitis. *Aliment Pharmacol Ther*. 2006 Jun 1;23(11):1525-34.
5. Nielsen OH, Vainer B, Rask-Madsen J. Non-IBD and noninfectious colitis. *Nat Clin Pract Gastroenterol Hepatol*. 2008 Jan;5(1):28-39.
6. Beaugerie L; Pardi DS. Review article: drug-induced microscopic colitis - proposal for a scoring system and review of the literature. *Aliment Pharmacol Ther*. 2005 Aug 15;22(4):277-84.
7. Chande N, McDonald JW, Macdonald JK. Interventions for treating collagenous colitis. *Cochrane Database Syst Rev*. 2008 Apr 16;(2):CD003575.
8. Chande N, McDonald JW, Macdonald JK. Interventions for treating lymphocytic colitis. *Cochrane Database Syst Rev*. 2008 Apr 16;(2):CD006096.
9. Nyhlin N, Bohr J, Eriksson S, Tysk C. Microscopic colitis: a common and an easily overlooked cause of chronic diarrhoea. *Eur J Intern Med*. 2008 May;19(3):181-6.

Contributors:

Matthew Short

Editor: Brett White